Chrono Therapeutics' anti-smoking device has undergone a clinical trial in adult, male smokers and the data showed a statistically significant reduction in nicotine cravings.
The transdermal drug delivery device, times nicotine delivery to when smokers have their strongest cravings.
It's designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of 'peaks and troughs' of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.
Wende Hutton, general partner at Canaan Partners and a member of Chrono Therapeutics’ board of directors, said: “Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging.
Quitting smoking is one of the simplest ways to improve global public health, but as the dismal efficacy of current therapies demonstrates, it is also one of the hardest. I’m very excited to be working with a company that has the potential to solve such a serious problem.”